

## Vitae Pharmaceuticals Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 02-Aug-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

    Phase 1 Clinical..... 11

    Discovery..... 27

[Return to Table of Contents](#)

# Vitae Pharmaceuticals Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Vitae Pharmaceuticals Inc
<b>Parent Company Name</b>	Vitae Pharmaceuticals Inc
<b>Website</b>	<a href="http://vitaepharma.com/">http://vitaepharma.com/</a>
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	7
<b>Number of Inactive Drugs</b>	10
<b>Number of Patents as Owner</b>	57
<b>Number of Patents as Third Party</b>	2
<b>Number of Deals</b>	6
<b>Key Indications</b>	Alzheimers disease,Hypertension,Atherosclerosis,Glaucoma,Metabolic syndrome X,Non-insulin dependent diabetes,Autoimmune disease,Dermatological disease,Cognitive disorder,Anxiety disorder,Diabetes mellitus,Neurodegenerative disease
<b>Key Target-based Actions</b>	Beta secretase 1 inhibitor,Liver X receptor beta agonist,11-Beta hydroxysteroid dehydrogenase 1 inhibitor,Renin inhibitor,Beta secretase inhibitor,Liver X receptor agonist,Retinoic acid receptor gamma antagonist,Aspartic protease inhibitor,Beta amyloid antagonist,Retinoid Z receptor gamma antagonist
<b>Key Technologies</b>	Small molecule therapeutic,Oral formulation,Dermatological formulation,Formulation powder,Tablet formulation,Crystalline form,Salt

## COMPANY PROFILE

### SUMMARY

Vitae Pharmaceuticals (formerly Concurrent Pharmaceuticals), based in Fort Washington, PA and founded in May 2001, is a clinical-stage biopharmaceutical company focused on innovative drug discovery and development of small molecules in the areas of chronic kidney disease, diabetes, atherosclerosis and Alzheimer's disease. In January 2005, the company changed its name from Concurrent to Vitae.

### LICENSING AGREEMENTS

In May 2007, Quest licensed Vitae's selective retinoic acid receptor agonists and antagonists and rexinoids for cancer. Quest also acquired a technology platform, intellectual property and a small molecule library.

In May 2004, Concurrent acquired rights to certain of Allergan Inc's preclinical programs and its retinoid and rexinoid nuclear receptor research portfolio.

### FINANCIAL

In January 2015, the company initiated a proposed follow-on public offering of 3 million shares of its common stock. At that time, the company expected to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares. In January 2015, the company priced its follow-on public offering at \$11.90 per share, with underwriters granted the 30-day purchase option. At that time, the offering was expected to close on or about January 28, 2015. later that month, the public offering was closed and the company planned to raise aggregate net proceeds of approximately \$37.8 million. A total of 3,450,000 shares of its common stock were sold at \$11.90 per share.

In December 2014, the company was added to the Russell 2000 and 3000 indices.

In September 2014, the company priced its initial public offering of 6,875,000 shares of common stock at \$8.00 per share and the underwriters were granted a 30-day option to purchase up to an additional 1,031,250 shares of common stock at the initial public offering price to cover any over-allotments. By that time, the shares began trading on NASDAQ global market under the ticker symbol "VTAE". Later that month, the offering was closed and the company planned to raise aggregate net proceeds of approximately \$48.4 million. In October 2014, the underwriters fully exercised their option to purchase the additional shares at \$8.00 each, and expected to raise net proceeds of approximately \$56 million.

[Return to Table of Contents](#)



In January 2012, the company secured a \$15 million senior credit facility from Oxford Finance and Silicon Valley Bank.

In October 2008, Vitae entered into a \$13 million loan agreement. The company planned to use the funds to support the initial clinical development of its renin inhibitor program and to support the ongoing development of its BACE program.

By August 2006, Vitae's investors included Prospect Venture Partners, Venrock Associates, New Enterprise Associates, Atlas Venture, Wellcome Trust, Intel Capital and Allergan Corporation.

In January 2005, Vitae secured \$34 million in equity financing, which would be used to accelerate the company's programs and to advance them into clinical trials.


In January 2004, Concurrent completed a series B preferred stock financing totaling \$15 million.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Dermatological disease	1	4	5
Degeneration	2	1	3
Neoplasm	0	3	3
Neurological disease	2	1	3
Metabolic disorder	2	1	3
Immune disorder	1	2	3
Endocrine disease	1	1	2
Hematological disease	0	2	2
Cardiovascular disease	2	0	2
Gastrointestinal disease	1	1	2
Respiratory disease	0	1	1
Nutritional disorder	0	1	1
Toxicity and intoxication	0	1	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 1 Clinical	4
Discovery	3
Discontinued	3
No Development Reported	7

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	2	0	0	0	4
Drug - Manufacturing/Supply	0	0	1	0	1
Drug - Asset Divestment	0	0	1	0	1

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Cardiovascular disease	0	1
Immune disorder	0	1
Dermatological disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	0	1
Phase 1	0	4

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)





## PATENTS \*

Indication	As Owner	As Third Party	Total
Immune disorder	12	0	12
Psychiatric disorder	36	0	36
Musculoskeletal disease	10	0	10
Neoplasm	11	0	11
Ocular disease	40	0	40
Metabolic disorder	45	0	45
Neurological disease	42	0	42
Nutritional disorder	19	0	19
Respiratory disease	8	0	8
Infectious disease	6	0	6
Injury	5	0	5
Toxicity and intoxication	1	0	1
Cardiovascular disease	51	0	51
Endocrine disease	38	0	38
Gastrointestinal disease	25	0	25
Genitourinary disease	20	0	20
Growth disorder	15	0	15
Hematological disease	7	0	7
Degeneration	21	0	21
Dermatological disease	11	0	11
Inflammatory disease	12	0	12
Gynecology and obstetrics	5	0	5

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### VTP-27999

#### VTP-27999 SNAPSHOT

<b>Drug Name</b>	VTP-27999
<b>Key Synonyms</b>	
<b>Originator Company</b>	Vitae Pharmaceuticals Inc
<b>Active Companies</b>	Vitae Pharmaceuticals Inc
<b>Inactive Companies</b>	GlaxoSmithKline plc
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Hypertension
<b>Target-based Actions</b>	Renin inhibitor
<b>Other Actions</b>	Antihypertensive
<b>Technologies</b>	Oral formulation;Small molecule therapeutic
<b>Last Change Date</b>	10-Jul-2015

#### VTP-27999 DEVELOPMENT PROFILE

##### SUMMARY

Vitae is developing VTP-27999 (structure shown), an orally-active, small molecule alkyl amine, which acts as a renin inhibitor, for the potential treatment of hypertension in chronic kidney disease patients,. A phase I trial began in September 2009 ; in October 2010, preliminary results were reported. In September 2013, the drug was listed as being in phase I development and at that time, a phase IIb study was planned to initiate in 2014. In May 2014, the company was seeking to outlicense the drug to initiate phase IIb studies.

GlaxoSmithKline (GSK) previously held rights to codevelop the program; however, in October 2008, Vitae reacquired rights.

#### VTP-27999 DEVELOPMENT STATUS


##### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Hypertension	US	Phase 1 Clinical	21-Sep-2009
GlaxoSmithKline plc	Hypertension	UK	Discontinued	21-Oct-2008


[Return to Table of Contents](#)




## VTP-27999 CHEMICAL STRUCTURES


CAS Registry Number:	Confidence Level:
	4
 <p>The chemical structure of VTP-27999 is a complex molecule. It features a central piperidine ring. On the left, a 2-chlorophenyl group is attached to the piperidine ring via a chiral center (wedge bond). This chiral center is also bonded to a 3-methoxypropyl group and a 2-chlorophenyl group. On the right, the piperidine ring is attached to a carbonyl group, which is further connected to a 2-methyl-2-(4-morpholinyl)ethyl group.</p>	
Name	Type
VTP-27999	Research Code

CAS Registry Number:	Confidence Level:
	5
 <p>The chemical structure of VTP-27999 is a complex molecule. It features a central piperidine ring. On the left, a 2-chlorophenyl group is attached to the piperidine ring via a chiral center (wedge bond). This chiral center is also bonded to a 3-methoxypropyl group and a 2-chlorophenyl group. On the right, the piperidine ring is attached to a carbonyl group, which is further connected to a 2-methyl-2-(4-morpholinyl)ethyl group.</p>	

CAS Registry Number:	Confidence Level:
	3
 <p>The chemical structure of VTP-27999 is a complex molecule. It features a central piperidine ring. On the left, a 2-chlorophenyl group is attached to the piperidine ring via a chiral center (wedge bond). This chiral center is also bonded to a 3-methoxypropyl group and a 2-chlorophenyl group. On the right, the piperidine ring is attached to a carbonyl group, which is further connected to a 2-methyl-2-(4-morpholinyl)ethyl group.</p>	

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	4
	

CAS Registry Number:	Confidence Level:
	3
	

### VTP-27999 DRUG NAMES

Names	Type
VTP-27999	Research Code
renin inhibitors (oral, hypertension), Vitae	

### VTP-27999 CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All

Hypertension											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	3	0	0	0	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

VTP-27999 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Vitae Pharmaceuticals Inc	0	1	0	0	1
GlaxoSmithKline plc	0	0	0	1	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	0	1	1

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Vitae Pharmaceuticals Inc	6	0	6
GlaxoSmithKline plc	1	4	5
Individual	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	4
Process	2



## BI-135585

### BI-135585 SNAPSHOT

Drug Name	BI-135585
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Boehringer Ingelheim Corp;Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Metabolic syndrome X;Non-insulin dependent diabetes
Target-based Actions	11-Beta hydroxysteroid dehydrogenase 1 inhibitor
Other Actions	Hypoglycemic agent
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	30-Jun-2015

### BI-135585 DEVELOPMENT PROFILE

#### SUMMARY

Vitae Pharmaceuticals and Boehringer Ingelheim are developing inhibitors of 11-beta hydroxysteroid dehydrogenase-1 (11-beta HSD-1) including BI-135585 (BI-135585-XX), for the potential oral treatment of type 2 diabetes. The companies are also investigating the program for other metabolic syndrome related indications . In January 2012, development was ongoing for other metabolic syndrome related indications ; in March 2013, this was still the case.

The companies were previously investigating the drug for obesity ; however, no further development was reported since June 2010.

### BI-135585 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Boehringer Ingelheim Corp	Non-insulin dependent diabetes	Germany	Phase 1 Clinical	29-Jun-2010
Vitae Pharmaceuticals Inc	Non-insulin dependent diabetes	US	Phase 1 Clinical	29-Jun-2010
Boehringer Ingelheim Corp	Metabolic syndrome X	Germany	Discovery	15-Oct-2007
Vitae Pharmaceuticals Inc	Metabolic syndrome X	US	Discovery	15-Oct-2007
Boehringer Ingelheim Corp	Obesity	Germany	No Development Reported	07-Dec-2011


[Return to Table of Contents](#)




Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Obesity	US	No Development Reported	07-Dec-2011

## BI-135585 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	3
 <p>The chemical structure of BI-135585 is a complex molecule. It features a central six-membered ring containing an oxygen atom and a carbonyl group. This ring is substituted with a 4-fluorophenyl group, a 2-hydroxyethyl group, and a side chain. The side chain consists of a methylene group attached to a chiral center (marked with a wedge bond), which is further connected to a biphenyl system. The biphenyl system has a 2,4-difluorophenyl group at the end.</p>	

CAS Registry Number:	Confidence Level:
	4
 <p>The chemical structure of BI-135585 is a complex molecule. It features a central six-membered ring containing an oxygen atom and a carbonyl group. This ring is substituted with a 4-fluorophenyl group, a 2-hydroxyethyl group, and a side chain. The side chain consists of a methylene group attached to a chiral center (marked with a wedge bond), which is further connected to a biphenyl system. The biphenyl system has a 2,4-difluorophenyl group at the end.</p>	

CAS Registry Number:	Confidence Level:
	3
 <p>The chemical structure of BI-135585 is a complex molecule. It features a central six-membered ring containing an oxygen atom and a carbonyl group. This ring is substituted with a 4-fluorophenyl group, a 2-hydroxyethyl group, and a side chain. The side chain consists of a methylene group attached to a chiral center (marked with a wedge bond), which is further connected to a biphenyl system. The biphenyl system has a 2,4-difluorophenyl group at the end.</p>	

[Return to Table of Contents](#)

## BI-135585 DRUG NAMES

Names	Type
11-beta HSD-1 inhibitors (metabolic disorders), Vitae/Boehringer Ingelheim	
11-beta hydroxysteroid dehydrogenase-1 inhibitors (metabolic disorders), Vitae/Boehringer Ingelheim	
BI-135585	Research Code
BI-135585-XX	Research Code

## BI-135585 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Non-insulin dependent diabetes											
0	0	0	0	0	0	0	4	0	0	0	4

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	5	0	0	0	5

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)



#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Boehringer Ingelheim Corp	0	0	1	0	1
Vitae Pharmaceuticals Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

## VTP-37948

### VTP-37948 SNAPSHOT

Drug Name	VTP-37948
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Boehringer Ingelheim Corp;Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Alzheimers disease
Target-based Actions	Beta secretase inhibitor;Beta secretase 1 inhibitor
Other Actions	Neuroprotectant;Nootropic agent
Technologies	Formulation powder;Oral formulation;Small molecule therapeutic;Tablet formulation
Last Change Date	29-Jul-2015

### VTP-37948 DEVELOPMENT PROFILE

#### SUMMARY

Vitae Pharmaceuticals, in collaboration with Boehringer Ingelheim, is developing VTP-37948 (BI-1181181), a lead from orally-active BACE (beta-secretase) inhibitors including BACE1 inhibitors, for the potential treatment of Alzheimer's disease (AD). In February 2014, a phase I trial was initiated in Germany. In May 2014, a phase I trial was initiated in Belgium. In October 2014, top-line results from two phase I trials were reported. At that time, Vitae planned to initiate another phase I trial in Germany. In February 2015, Vitae voluntarily placed a temporary clinical hold to further investigate skin reactions observed in some study participants during the multiple rising dose trial. However, in July 2015, Boehringer Ingelheim informed Vitae that it was to withdraw involvement in developing the program for strategic business reasons. The partnership was to end on October 21, 2015.

### VTP-37948 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Boehringer Ingelheim Corp	Alzheimers disease	Belgium	Phase 1 Clinical	19-May-2014
Boehringer Ingelheim Corp	Alzheimers disease	Germany	Phase 1 Clinical	20-Feb-2014
Vitae Pharmaceuticals Inc	Alzheimers disease	Belgium	Phase 1 Clinical	19-May-2014
Vitae Pharmaceuticals Inc	Alzheimers disease	Germany	Phase 1 Clinical	20-Feb-2014

[Return to Table of Contents](#)



VTP-37948 DRUG NAMES

Names	Type
BACE inhibitor program (oral, Alzheimer's disease), Vitae Pharmaceuticals	
BI-1181181	Research Code
VTP-37948	Research Code
beta-secretase inhibitors (oral, Alzheimer's disease), Vitae/Boehringer Ingelheim	

VTP-37948 CLINICAL TRIALS


Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	4	0	0	0	4


VTP-37948 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Active Deals  
Total: 1




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Boehringer Ingelheim Corp	0	0	1	0	1
Vitae Pharmaceuticals Inc	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1



## VTP-43742

### VTP-43742 SNAPSHOT

Drug Name	VTP-43742
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Autoimmune disease
Target-based Actions	Retinoic acid receptor gamma antagonist
Other Actions	Immunomodulator
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	16-Jul-2015

### VTP-43742 DEVELOPMENT PROFILE

#### SUMMARY

Vitae Pharmaceuticals is developing VTP-43742, a lead from retinoid-acid receptor (RAR) related orphan receptor gamma t (ROR gamma t) inhibitors for the potential oral treatment of autoimmune disease,. By June 2015, an IND was filed with the US FDA; later that month, a phase I study was initiated and results were expected in the second half of 2015; at that time, a phase I psoriasis trial was expected to be initiated in the third quarter of 2015 and results were expected by the end of the year . In March 2013, the company was seeking to outlicense the program .

### VTP-43742 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Autoimmune disease	US	Phase 1 Clinical	29-Jun-2015

### VTP-43742 DRUG NAMES

Names	Type
ROR gamma t inhibitors (autoimmune disease), Vitae	
VTP-43742	Research Code
retinoid-acid receptor-related orphan receptor gamma t inhibitors (autoimmune disease), Vitae	

[Return to Table of Contents](#)

VTP-43742 CLINICAL TRIALS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

## VTP-38443

### VTP-38443 SNAPSHOT

Drug Name	VTP-38443
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Atherosclerosis
Target-based Actions	Liver X receptor beta agonist
Other Actions	Antiarteriosclerotic
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	02-Jul-2015

### VTP-38443 DEVELOPMENT PROFILE

#### SUMMARY

Vitae Pharmaceuticals is investigating VTP-38443 (VTP-4), the lead from a small molecule selective partial Liver X Receptor (LXR) beta agonists for the potential oral treatment of acute coronary syndrome including atherosclerosis, ,,. In October 2010, the program was listed as being in lead optimization ; in June 2012, the lead compound was in dose ranging toxicity studies. In September 2013, the program was listed as being in preclinical development ; in June 2015, the drug was in lead discovery/optimization. In September 2013, the company was seeking to outlicense the program.

The company is also investigating LXR modulator for dermatology and LXR modulator for Alzheimers disease.

### VTP-38443 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Atherosclerosis	US	Discovery	29-Sep-2010

[Return to Table of Contents](#)

VTP-38443 DRUG NAMES

Names	Type
LXR modulators (atherosclerosis), Vitae Pharmaceuticals	
Liver X Receptor modulators (atherosclerosis), Vitae Pharmaceuticals	
VTP-38443	Research Code
VTP-4	Research Code
antiarteriosclerotic agents (small molecule therapeutics), Vitae Pharmaceuticals	
partial Liver X Receptor beta agonists (atherosclerosis), Vitae Pharmaceuticals	

[Return to Table of Contents](#)

## VTP-38543

### VTP-38543 SNAPSHOT

Drug Name	VTP-38543
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Dermatological disease
Target-based Actions	Liver X receptor agonist
Other Actions	Dermatological agent
Technologies	Dermatological formulation;Small molecule therapeutic
Last Change Date	30-Jul-2015

### VTP-38543 DEVELOPMENT PROFILE

#### SUMMARY

Vitae Pharmaceuticals is investigating VTP-38543, a liver X receptor (LXR) agonist, for the potential topical treatment of dermatological disease, including atopic dermatitis,. In March 2013, the program was in preclinical development . In March 2015, a safety and pharmacokinetic, phase I trial was planned to be initiated in the second half of 2015.

### VTP-38543 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Dermatological disease	US	Discovery	21-Mar-2013

### VTP-38543 DRUG NAMES

Names	Type
LXR modulator (dermatological disease), Vitae	
VTP-38543	Research Code
liver X receptor modulator (dermatological disease), Vitae	

[Return to Table of Contents](#)





## BIVP-1

### BIVP-1 SNAPSHOT

Drug Name	BIVP-1
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Boehringer Ingelheim Corp;Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Alzheimers disease
Target-based Actions	Beta secretase 1 inhibitor
Other Actions	Beta amyloid synthesis inhibitor;Neuroprotectant
Technologies	Small molecule therapeutic
Last Change Date	29-Jul-2015

### BIVP-1 DEVELOPMENT PROFILE

#### SUMMARY

Boehringer Ingelheim and Vitae Pharmaceuticals are investigating BIVP-1 (BI-1147560; VTP-36951), a BACE1 inhibitor, for the potential treatment of Alzheimer's disease . In July 2014, preclinical data were presented. By May 2015, all IND enabling studies had been completed. In March 2015, Vitae planned to initiate a phase I trial by the end of 2015. However, in July 2015, Boehringer Ingelheim informed Vitae that it was to withdraw involvement in developing the drug for strategic business reasons. The partnership was to end on October 21, 2015.

### BIVP-1 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Boehringer Ingelheim Corp	Alzheimers disease	Germany	Discovery	16-Jul-2014
Vitae Pharmaceuticals Inc	Alzheimers disease	US	Discovery	16-Jul-2014

[Return to Table of Contents](#)




BIVP-1 DRUG NAMES

Names	Type
BACE1 inhibitor (Alzheimer's disease), Vitae Pharmaceuticals\Boehringer Ingelheim	
BI-1147560	Research Code
BIVP-1	Research Code
VTP-36951	Research Code

BIVP-1 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Vitae Pharmaceuticals Inc	1	0	0	0	1
Boehringer Ingelheim Corp	0	0	1	0	1

[Return to Table of Contents](#)



Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

